4 completed, 3 active not recruiting. 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 4, Active not recruiting 3 |
Follow DBV Technologies: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) DBV712 250 mcg, Placebo - Allergy, Peanut Allergy | Phase 3 | Active not recruiting | DBV Technologies | 480 | 2025-06-24 | 2026-07-22 |
| Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age DBV712, Placebo - Allergy, Peanut | Phase 3 | Active not recruiting | DBV Technologies | 600 | 2023-02-21 | 2026-01-22 |
| Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children DBV712 250 mcg - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 304 | 2018-12-06 | 2026-10-28 |
| Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part A Placebo - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 414 | 2017-07-31 | 2024-12-16 |
| Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children Viaskin Peanut 250µg - Peanut Allergy | Phase 3 | Active not recruiting | DBV Technologies | 300 | 2017-01-23 | 2020-12-02 |
| Safety Study of Viaskin Peanut to Treat Peanut Allergy Viaskin Peanut 250 µg, Placebo - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 393 | 2016-10-25 | 2026-10-08 |
| Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy Viaskin Peanut 250mcg, Placebo - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 500 | 2015-12-01 | 2025-06-18 |
Peanut Hypersensitivity (7) · Food Hypersensitivity (3) · Hypersensitivity (2) · Nut and Peanut Hypersensitivity (2)
United States (7) · Canada (6) · Australia (5) · Ireland (5) · Germany (4) · France (3) · Netherlands (3) · United Kingdom (3) · Spain (2)
PMID 37163622, PMID 30794314, PMID 31442495, PMID 32502548, PMID 33259921, PMID 39956162, PMID 40023371, PMID 40204253